Miki Garcia is a Dermatology physician. OpenAlex indexes 11 publications with 511 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Botanix SB IncProgram year20251 payment
- ABBVIE INC.Program year202511 payments
- Galderma Laboratories, L.P.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
21.4%Corticosteroid9%Triamcinolone Acetonide55%Triamcinolone acetonide45%Part D + Part B≥27 patientsInterleukin-4 Receptor alpha Antagonist3.5%Dupixent Pen100%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
21.2%Calcineurin inhibitor8.8%Tacrolimus100%Part D≥38 patientsRetinoid4.4%Tretinoin100%Part D≥14 patients+ 3 more classes in this area
Respiratory
14.9%Corticosteroid8.3%Mometasone Furoate100%Part D≥35 patientsRNA Synthetase Inhibitor Antibacterial4.6%Mupirocin100%Part D≥24 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effective Strategies for the Management of Pyoderma Gangrenosum: A Comprehensive Review
Acta Dermato Venereologica
2015 - 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series
Journal of the American Academy of Dermatology
2015 - Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring
Clinical Reviews in Allergy & Immunology
2012 - Hyperpigmented burn scar improved with a fractionated 1550 nm non-ablative laser
Dermatology Online Journal
2012
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Andrew Blauvelt, MD
University of Maryland School of Medicine
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”